Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $17.00 Average Price Target from Analysts
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned a consensus rating of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock […]
More Stories
A Good Girl’s Guide to Murder Season 2: Release Date, Cast, and Synopsis
The notable acting skills of Emma Myers have made her one of the fastest-growing actors in the industry. Her influence...
MAP Violation: Are You Lacking Control Over Your Brand?
The logo, tagline, color, voice, tone, and especially the pricing echo your brand’s reputation and distinct identity in the marketplace....
15 Best Franchise Businesses in America with their Franchise Fees
Want to start your own business? Confused whether it will work or not. I have brought 15 of the best...
Grey’s Anatomy Season 23 is Confirmed! Kevin McKidd Has Left the Show
The longest-running show on ABC Network, Grey’s Anatomy, is currently streaming on its official channel. The series has been getting...
Love is Blind Couple, Chelsea and Kwame are Separating After 4 years Together
Yes, you heard it right. The famous couple from season 4 of Love is Blind is parting ways. The couple...
Netflix’s Romantic Drama, Forever Season 2 is Returning
Forever starring Lovie Simone is returning for its second season soon. Want to know more about the series details? Keep...